Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/2147/7/08: GlaxoSmithKline v Sanofi Pasteur MSD – Gardasil press release and PR agency emails

A Gardasil press release and follow-up PR emails after the UK chose Cervarix for the national HPV programme…

8 Mar 2026

Anonymous v GlaxoSmithKline: POINTS COPD audit service (AUTH/2178/10/08) – No breach

Anonymous complaint questioned GSK’s POINTS COPD audit service as a potential rep monitoring/inducement tool. Panel found clear separation…

8 Mar 2026

AUTH/2198/10/9: Primary Care Trust v Solvay β€” Not stated

PMCPA case summary for AUTH/2198/10/9 (Primary Care Trust v Solvay). The provided case text contains no details on…

8 Mar 2026

Otsuka Europe voluntary admission: unclear SPC update communications for Jinarc and out-of-date package leaflet (AUTH/3169/3/19)

Otsuka Europe admitted potential Code issues after confusing affiliate communications on parallel Jinarc SPC variations and an out-of-date…

8 Mar 2026

Sanofi-Aventis: HSJ β€˜special report’ found to be disguised promotion for dronedarone (Clause 12.1)

A sponsored HSJ β€˜special report’ on atrial fibrillation looked like independent editorial and favoured dronedarone. PMCPA ruled Sanofi-Aventis…

8 Mar 2026

AstraZeneca & Bristol-Myers Squibb: Onglyza advert in Health Service Journal (audience targeting) – no breach on appeal

Two public complaints said an Onglyza advertorial in Health Service Journal was inappropriate/too technical and potentially public-facing. Panel…

8 Mar 2026

AUTH/2473/1/12: Vifor Pharma – Ferinject journal ads not UK-certified (Clause 14.1 x3)

Vifor voluntarily admitted three Ferinject ads placed by global colleagues in international journals were not certified under the…

8 Mar 2026

Gedeon Richter: Barcelona Esmya meeting invitationsβ€”unacceptable arrangements, lack of certification, and pre-licence promotion (AUTH/2575/2/13)

Ex-employee complaint about Esmya meeting invites for Barcelona. Panel found unacceptable meeting arrangements and lack of certification (2013),…

8 Mar 2026

Napp Pharmaceuticals: Norway meeting for UK HCPs to discuss Remsima switching ruled an inducement (AUTH/2795/9/15)

Napp funded UK HCPs to attend a 2‑day Remsima promotional meeting in Norway. PMCPA found no clear reason…

8 Mar 2026

AUTH/2702/3/14: General Practitioner v Pfizer β€” remote detailing access via call scheduling (no breach)

A GP alleged a Pfizer representative used subterfuge and urgency to get through to him via reception. The…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training